NCT01349049 - Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 21, 2011

Primary Completion Date

January 20, 2015

Study Completion Date

January 9, 2018

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

PLX3397

Maximum Tolerated Dose of PLX3397 will be administered orally, twice daily.

DRUG

PLX3397

The drug product is available in capsule form, to be taken orally.

Trial Locations (9)

Memorial Sloan Kettering Cancer Center, New York

New York Presby Hospital, Weill Medical College at Cornell University, New York

Roswell Park Cancer Institute, Buffalo

University of Pennsylvania, Abramson Cancer Center, Philadelphia

Johns Hopkins University, Baltimore

Northwestern University, Chicago

UCSF Helen Diller Family Family Comprehensive Cancer Center, San Francisco

Fred Hutchinson Cancer Research Center, Seattle

Dana Farber Cancer Institute, Boston